# US 2024/0189308 A1 · Methods for treating cholestasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189308 A1
- Document ID: US20240189308A1
- Status: Published application
- Kind: A1
- Application number: 18/417,725
- Filed: 2024-01-19
- Published: 2024-06-13
- Earliest claimed: 2019-02-12
- Assignees: Mirum Pharmaceuticals, Inc.
- Applicants: Mirum Pharmaceuticals, Inc.
- Inventors: Thomas JAECKLIN; Alejandro DORENBAUM
- Web page: https://patentgrep.com/patent/US20240189308A1

## CPC

- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 31/7042: Compounds having saccharide radicals and heterocyclic rings
- A61K 38/05: Dipeptides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 17/04: Antipruritics
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.

## Claims

### Claim at position 1

1-102. (canceled)

### Claim 103

A method for treating progressive familial intrahepatic cholestasis (PFIC) in a subject in need of such treatment comprising administering to the subject maralixibat in an amount of from about 560 μg/kg/day to about 1400 μg/kg/day.

### Claim 104 (depends on 103)

The method of claim 103, wherein maralixibat is administered in an amount of about 560 μg/kg/day.

### Claim 105 (depends on 103)

The method of claim 103, wherein maralixibat is administered in an amount of about 1100 μg/kg/day.

### Claim 106 (depends on 103)

The method of claim 103, wherein maralixibat is administered in an amount of about 1200 μg/kg/day.

### Claim 107 (depends on 103)

The method of claim 103, wherein maralixibat is administered in an amount from about 10 mg/day to about 100 mg/day.

### Claim 108 (depends on 107)

The method of claim 107, wherein maralixibat is administered in an amount from about 20 mg/day to about 80 mg/day.

### Claim 109 (depends on 103)

The method of claim 103, wherein the PFIC is selected from PFIC type 1, PFIC type 2, and PFIC type 3.

### Claim 110 (depends on 109)

The method of claim 109, wherein the PFIC is PFIC type 1.

### Claim 111 (depends on 109)

The method of claim 109, wherein the PFIC is PFIC type 2.

### Claim 112 (depends on 109)

The method of claim 109, wherein the PFIC is PFIC type 3.

### Claim 113 (depends on 103)

The method of claim 103, wherein maralixibat is administered once daily (QD).

### Claim 114 (depends on 103)

The method of claim 103, wherein maralixibat is administered twice daily (BID).

### Claim 115 (depends on 103)

The method of claim 103, wherein maralixibat is administered for at least 18 weeks.

### Claim 116 (depends on 103)

The method of claim 103, wherein maralixibat is administered for at least 2 years.

### Claim 117 (depends on 103)

The method of claim 103, wherein maralixibat is administered for at least 3 years.

### Claim 118 (depends on 103)

The method of claim 103, wherein the subject exhibits below normal height or weight prior to the administration of maralixibat.

### Claim 119 (depends on 103)

The method of claim 103, wherein the subject experiences pruritus prior to the administration of maralixibat.

### Claim 120 (depends on 103)

The method of claim 103, wherein the subject is a pediatric subject.

### Claim 121 (depends on 103)

The method of claim 103, wherein the subject is at least 1 year of age.

### Claim 122 (depends on 103)

The method of claim 103, wherein maralixibat is administered prior to ingestion of food.

### Claim 123 (depends on 103)

The method of claim 103, wherein maralixibat is administered orally.
